Health
FDA revokes EUA for monoclonal antibody therapy bamlanivimab to treat patients with COVID-19 – News-Medical.Net
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab,…
Today, the U.S. Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment…
-
Noosa News18 hours agoLuxury caravan manufacturer Zone RV collapses into administration
-
General19 hours agoWoman in her 20s dies after dog attack in Western Australia’s north
-
General17 hours agoCase against teens charged over Adelaide shopping centre stabbing could move to adult court
-
General5 hours agoBoard stacking allegations as RACP directors call snap meeting